Navigation Links
AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
Date:2/17/2011

ALISO VIEJO, Calif., Feb. 17, 2011 /PRNewswire/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced the promotion of Gregory J. Flesher to the position of Senior Vice President of Corporate Development and Chief Business Officer.  In this role, Mr. Flesher will oversee corporate strategy, business development, program management, and business operations.

"Greg has shown exceptional leadership over the past several years and has played a key role in the transformation of AVANIR into a commercial-stage organization," said Keith Katkin, President and Chief Executive Officer.  "His broad pharmaceutical background in business development, sales and marketing, and research and development provides a strong foundation which will help AVANIR grow into a successful CNS company.  I look forward to Greg's continued contributions to the executive management team."

Mr. Flesher has over 16 years of experience in the pharmaceutical industry.  He was previously Vice President of Business Development for AVANIR, with responsibility for business transactions, intellectual property, and NUEDEXTA™ lifecycle planning.  Prior to joining the Company, he held various positions of increasing responsibility at InterMune Inc., Amgen Inc., and Eli Lilly and Company.

Mr. Flesher graduated from Purdue University with a degree in Biology and has completed his doctorate coursework in Biochemistry and Molecular Biology at Indiana University School of Medicine.

About AVANIR Pharmaceuticals, Inc.

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about AVANIR, please visit www.avanir.com.

AVANIR™ and NUEDEXTA™ are trademarks owned by AVANIR Pharmaceuticals, Inc.

©2011 AVANIR Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
2. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
3. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
4. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
6. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
7. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
8. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
9. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
10. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
11. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):